Morgan Dempsey Capital Management’s Gilead Sciences GILD Stock Holding History

Morgan Dempsey Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100	Closed	-$8.38K	–	134
2024 Q3	$8.38K	Sell	100 -100	-50%	-$7.63K	﹤0.01%	114
2024 Q2	$13.7K	Buy	+200	New	+$13.3K	﹤0.01%	75
2023 Q4	–	Sell	-200	Closed	-$15K	–	123
2023 Q3	$15K	Hold	200	–	–	﹤0.01%	70
2023 Q2	$15.4K	Hold	200	–	–	﹤0.01%	75
2023 Q1	$16.6K	Hold	200	–	–	﹤0.01%	74
2022 Q4	$17.2K	Hold	200	–	–	﹤0.01%	82
2022 Q3	$12K	Hold	200	–	–	﹤0.01%	91
2022 Q2	$12K	Hold	200	–	–	﹤0.01%	78
2022 Q1	$12K	Hold	200	–	–	﹤0.01%	79
2021 Q4	$15K	Hold	200	–	–	﹤0.01%	74
2021 Q3	$14K	Buy	+200	New	+$14.1K	﹤0.01%	71

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Dempsey Capital Management's GILD Position: Q4 2025 in Review

Morgan Dempsey Capital Management sold out of Gilead Sciences (GILD) in Q4 2025, closing a stake of 350 shares — an estimated $38.9K sold.

Morgan Dempsey Capital Management first reported a position in GILD in Q1 2019 and held it in 27 quarters. The position peaked at $14M in Q4 2022. 2,217 funds tracked by Wall St. Rank hold GILD as of Q4 2025.

Morgan Dempsey Capital Management reported no remaining Gilead Sciences position as of Q4 2025 after selling out during the quarter.
Morgan Dempsey Capital Management sold 350 Gilead Sciences shares in Q4 2025, an estimated $38.9K.
Morgan Dempsey Capital Management first reported a position in Gilead Sciences in Q1 2019 and held it in 27 quarters.
Morgan Dempsey Capital Management's Gilead Sciences position peaked at $14M in Q4 2022.
2,217 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.

Based on Morgan Dempsey Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.